Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

M. Gentile; E.A. Martino; A. Visentin; M. Coscia; G. Reda; P. Sportoletti; F.R. Mauro; L. Laurenti; M. Varettoni; R. Murru; A. Chiarenza; E. Vigna; F. Mendicino; E. Lucia; S. Bossio; A.G. Recchia; R. Moia; D. Pietrasanta; G. Loseto; U. Consoli; I. Scortechini; F.M. Rossi; A. Zucchetto; H. Al-Janazreh; C. Vitale; G. Tripepi; G. D’Arrigo; I. Angeletti; R. Bomben; A. Neri; G. Cutrona; G. Fronza; F. Di Raimondo; G. Gaidano; A. Cuneo; R. Foà; M. Ferrarini; L. Trentin; V. Gattei; F. Morabito

doi:10.1038/s41408-020-00358-3

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

M. Gentile, E.A. Martino, A. Visentin, M. Coscia, G. Reda, P. Sportoletti, F.R. Mauro, L. Laurenti, M. Varettoni, R. Murru, A. Chiarenza, E. Vigna, F. Mendicino, E. Lucia, S. Bossio, A.G. Recchia, R. Moia, D. Pietrasanta, G. Loseto, U. ConsoliI. Scortechini, F.M. Rossi, A. Zucchetto, H. Al-Janazreh, C. Vitale, G. Tripepi, G. D’Arrigo, I. Angeletti, R. Bomben, A. Neri, G. Cutrona, G. Fronza, F. Di Raimondo, G. Gaidano, A. Cuneo, R. Foà, M. Ferrarini, L. Trentin, V. Gattei, F. Morabito

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	92
Journal	Blood Cancer Journal
Volume	10
Issue number	9
DOIs	https://doi.org/10.1038/s41408-020-00358-3
Publication status	Published - 2020

Keywords

B lymphocyte receptor
idelalisib
rituximab
allogeneic stem cell transplantation
cancer growth
cancer staging
chronic lymphatic leukemia
clinical outcome
follow up
human
Letter
multivariate logistic regression analysis
overall survival
patient coding
predictive value
risk algorithm
scoring system
survival analysis
univariate analysis
validation study

Access to Document

10.1038/s41408-020-00358-3

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091129141&doi=10.1038%2fs41408-020-00358-3&partnerID=40&md5=68820bf589052cb1d91957e10d7fddb3

Cite this

Gentile, M., Martino, E. A., Visentin, A., Coscia, M., Reda, G., Sportoletti, P., Mauro, F. R., Laurenti, L., Varettoni, M., Murru, R., Chiarenza, A., Vigna, E., Mendicino, F., Lucia, E., Bossio, S., Recchia, A. G., Moia, R., Pietrasanta, D., Loseto, G., ... Morabito, F. (2020). Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab. Blood Cancer Journal, 10(9), [92]. https://doi.org/10.1038/s41408-020-00358-3

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab. / Gentile, M.; Martino, E.A.; Visentin, A.; Coscia, M.; Reda, G.; Sportoletti, P.; Mauro, F.R.; Laurenti, L.; Varettoni, M.; Murru, R.; Chiarenza, A.; Vigna, E.; Mendicino, F.; Lucia, E.; Bossio, S.; Recchia, A.G.; Moia, R.; Pietrasanta, D.; Loseto, G.; Consoli, U.; Scortechini, I.; Rossi, F.M.; Zucchetto, A.; Al-Janazreh, H.; Vitale, C.; Tripepi, G.; D’Arrigo, G.; Angeletti, I.; Bomben, R.; Neri, A.; Cutrona, G.; Fronza, G.; Di Raimondo, F.; Gaidano, G.; Cuneo, A.; Foà, R.; Ferrarini, M.; Trentin, L.; Gattei, V.; Morabito, F.

In: Blood Cancer Journal, Vol. 10, No. 9, 92, 2020.

Research output: Contribution to journal › Article › peer-review

Gentile, M, Martino, EA, Visentin, A, Coscia, M, Reda, G, Sportoletti, P, Mauro, FR, Laurenti, L , Varettoni, M, Murru, R, Chiarenza, A , Vigna, E, Mendicino, F, Lucia, E, Bossio, S, Recchia, AG, Moia, R, Pietrasanta, D, Loseto, G, Consoli, U, Scortechini, I, Rossi, FM , Zucchetto, A, Al-Janazreh, H, Vitale, C, Tripepi, G, D’Arrigo, G, Angeletti, I, Bomben, R , Neri, A , Cutrona, G , Fronza, G, Di Raimondo, F, Gaidano, G, Cuneo, A, Foà, R, Ferrarini, M, Trentin, L, Gattei, V & Morabito, F 2020, 'Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab', Blood Cancer Journal, vol. 10, no. 9, 92. https://doi.org/10.1038/s41408-020-00358-3

Gentile, M. ; Martino, E.A. ; Visentin, A. ; Coscia, M. ; Reda, G. ; Sportoletti, P. ; Mauro, F.R. ; Laurenti, L. ; Varettoni, M. ; Murru, R. ; Chiarenza, A. ; Vigna, E. ; Mendicino, F. ; Lucia, E. ; Bossio, S. ; Recchia, A.G. ; Moia, R. ; Pietrasanta, D. ; Loseto, G. ; Consoli, U. ; Scortechini, I. ; Rossi, F.M. ; Zucchetto, A. ; Al-Janazreh, H. ; Vitale, C. ; Tripepi, G. ; D’Arrigo, G. ; Angeletti, I. ; Bomben, R. ; Neri, A. ; Cutrona, G. ; Fronza, G. ; Di Raimondo, F. ; Gaidano, G. ; Cuneo, A. ; Foà, R. ; Ferrarini, M. ; Trentin, L. ; Gattei, V. ; Morabito, F. / Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab. In: Blood Cancer Journal. 2020 ; Vol. 10, No. 9.

@article{92a83a341b0e4ddab026e92fc3a1a22d,

title = "Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab",

keywords = "B lymphocyte receptor, idelalisib, rituximab, allogeneic stem cell transplantation, cancer growth, cancer staging, chronic lymphatic leukemia, clinical outcome, follow up, human, Letter, multivariate logistic regression analysis, overall survival, patient coding, predictive value, risk algorithm, scoring system, survival analysis, univariate analysis, validation study",

author = "M. Gentile and E.A. Martino and A. Visentin and M. Coscia and G. Reda and P. Sportoletti and F.R. Mauro and L. Laurenti and M. Varettoni and R. Murru and A. Chiarenza and E. Vigna and F. Mendicino and E. Lucia and S. Bossio and A.G. Recchia and R. Moia and D. Pietrasanta and G. Loseto and U. Consoli and I. Scortechini and F.M. Rossi and A. Zucchetto and H. Al-Janazreh and C. Vitale and G. Tripepi and G. D{\textquoteright}Arrigo and I. Angeletti and R. Bomben and A. Neri and G. Cutrona and G. Fronza and {Di Raimondo}, F. and G. Gaidano and A. Cuneo and R. Fo{\`a} and M. Ferrarini and L. Trentin and V. Gattei and F. Morabito",

note = "Export Date: 15 October 2020",

year = "2020",

doi = "10.1038/s41408-020-00358-3",

language = "English",

volume = "10",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

AU - Gentile, M.

AU - Martino, E.A.

AU - Visentin, A.

AU - Coscia, M.

AU - Reda, G.

AU - Sportoletti, P.

AU - Mauro, F.R.

AU - Laurenti, L.

AU - Varettoni, M.

AU - Murru, R.

AU - Chiarenza, A.

AU - Vigna, E.

AU - Mendicino, F.

AU - Lucia, E.

AU - Bossio, S.

AU - Recchia, A.G.

AU - Moia, R.

AU - Pietrasanta, D.

AU - Loseto, G.

AU - Consoli, U.

AU - Scortechini, I.

AU - Rossi, F.M.

AU - Zucchetto, A.

AU - Al-Janazreh, H.

AU - Vitale, C.

AU - Tripepi, G.

AU - D’Arrigo, G.

AU - Angeletti, I.

AU - Bomben, R.

AU - Neri, A.

AU - Cutrona, G.

AU - Fronza, G.

AU - Di Raimondo, F.

AU - Gaidano, G.

AU - Cuneo, A.

AU - Foà, R.

AU - Ferrarini, M.

AU - Trentin, L.

AU - Gattei, V.

AU - Morabito, F.

N1 - Export Date: 15 October 2020

PY - 2020

Y1 - 2020

KW - B lymphocyte receptor

KW - idelalisib

KW - rituximab

KW - allogeneic stem cell transplantation

KW - cancer growth

KW - cancer staging

KW - chronic lymphatic leukemia

KW - clinical outcome

KW - follow up

KW - human

KW - Letter

KW - multivariate logistic regression analysis

KW - overall survival

KW - patient coding

KW - predictive value

KW - risk algorithm

KW - scoring system

KW - survival analysis

KW - univariate analysis

KW - validation study

U2 - 10.1038/s41408-020-00358-3

DO - 10.1038/s41408-020-00358-3

M3 - Article

VL - 10

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 9

M1 - 92

ER -